Abstract: A signal processing chip includes: a receiving module, configured to receive a WLAN analog baseband signal from a baseband chip; an analog-to-digital conversion module, configured to convert the WLAN analog baseband signal into a WLAN digital baseband signal; a processing module, configured to process the WLAN digital baseband signal into a WLAN analog intermediate frequency signal; and a sending module, configured to send the WLAN analog intermediate frequency signal to a radio frequency processing apparatus.

Abstract: A display apparatus is disclosed The display apparatus includes a display, configured to present an image interface, the image interface includes a render layer and a display layer superimposed: and a controller, configured to obtain a target video resource and one or more recommended video resource associated with the target video resource; control the display layer to present the target video resource and output audio of the target video resource; and control the render layer to present the one or more recommended video resource simultaneously.

Abstract: A computer system is used to initiate a process to configure an external accessory for use with at least a first device management application. The computer system displays a prompt that includes an option to initiate a process to configure the external accessory for use with at least a first device management application. While displaying the prompt, the computer system optionally receives a selection and/or an input corresponding to a selection of an option to initiate a process to configure the external accessory for use with at least a first device management application.

Abstract: The present disclosure generally relates to user interfaces for enabling an activity using a computer system. In some embodiments, exemplary user interfaces for invoking an activity associated with an application are described. In some embodiments, exemplary user interfaces for customizing displayed content based on circumstances under which the content was invoked are described. In some embodiments, exemplary user interfaces for managing applications that were used to enable activities are described. In some embodiments, exemplary user interfaces for managing settings for applications used to enable activities are described.

Abstract: In an example method, a mobile device receives motion data obtained by one or more sensors over a time period, where the one or more sensors are worn by a user, The mobile device determines, based on the motion data, an impact experienced by the user during the time of period, and determines one or more of characteristics of the user. The mobile device determines, based on the motion data and the one or more characteristics of the user, a likelihood that the user requires assistance subsequent to the impact, and generates one or more notifications based on likelihood.

Abstract: In an example method, a mobile device obtains a database including a plurality of data records. Each data record includes an indication of a respective impact previously experienced by a user of the mobile device, and sensor data generated by one or more first sensors worn by the user during that impact. The mobile device obtains sensor data generated by one or more second sensors worn by the user over a period of time, and determines whether the user has fallen during the period of time based on the database and the additional sensor data. The mobile device generates one or more notifications based on the determination of whether the user has fallen during the period of time.

Abstract: The present disclosure generally relates to user interfaces for enabling an activity using a computer system. In some embodiments, exemplary user interfaces for invoking an activity associated with an application are described. In some embodiments, exemplary user interfaces for customizing displayed content based on circumstances under which the content was invoked are described. In some embodiments, exemplary user interfaces for managing applications that were used to enable activities are described. In some embodiments, exemplary user interfaces for managing settings for applications used to enable activities are described.

Abstract: In an example method, a mobile device receives motion data obtained by one or more sensors over a time period, where the one or more sensors are worn by a user, The mobile device determines, based on the motion data, an impact experienced by the user during the time of period, and determines one or more of characteristics of the user. The mobile device determines, based on the motion data and the one or more characteristics of the user, a likelihood that the user requires assistance subsequent to the impact, and generates one or more notifications based on likelihood.

Abstract: The invention provides compounds of Formula (I), immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.

Abstract: In an example method, a mobile device obtains a database including a plurality of data records. Each data record includes an indication of a respective impact previously experienced by a user of the mobile device, and sensor data generated by one or more first sensors worn by the user during that impact. The mobile device obtains sensor data generated by one or more second sensors worn by the user over a period of time, and determines whether the user has fallen during the period of time based on the database and the additional sensor data. The mobile device generates one or more notifications based on the determination of whether the user has fallen during the period of time.

Abstract: The invention provides compounds of Formula (I), immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.

Abstract: The invention provides compounds of Formula (I), immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.

Abstract: Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminum salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.

Abstract: The invention provides compounds of Formula (I), immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.

Abstract: The invention provides a compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.

Abstract: The invention provides a compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.

Abstract: The invention provides a compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.

Abstract: The invention provides a compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.

Abstract: Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.

Abstract: Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminum salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.